More than a year after the declaration of the pandemic of the new Coronavirus, in equestrian terms, the race for a vaccine against Covid-19 is still in full swing, where governments and pharmaceutical competitors seek to compete to create the best and most effective vaccine to counteract the levels of contagions, deaths and to grant them political and economic capital.

The race to reach an effective vaccine against Covid-19 seems to have no place of arrival, this if we evaluate that governments, health institutions and pharmaceutical companies are competing with enormous interest in creating a vaccine against Covid-19 that can give a respite to the economy, to health and some normality to reestablish our usual lifestyles.

In this regard, countries such as the USA, China, Russia, India, among others, have been presenting projects whose initiatives generally come from economically strong private sectors in supposed alliances with prestigious academic universities and some prominent international research centers.

Some of the vaccines developed have not shown effectiveness, however, some still remain at the head of the race to combat the pandemic of the new Coronavirus, in this sense, it is important to mention that in recent weeks the race has focused on which vaccine presents greater immunization effectiveness.

However, among the vaccines with the highest immunization effectiveness is the Sputnik Light vaccine developed in Russia. According to tests carried out as part of Russia's mass vaccination program, Sputnik Light, with the application of a single dose, allows the immunization of a greater number of people in a shorter period of time.

[1] RDIF Single dose vaccine, Sputnik Light, authorized for use in Russia. 2021. Article: Online access

[2] Reuters Russia authorises single-dose Sputnik Light COVID vaccine for use - RDIF. 2021. Article: Online access